|
US8343966B2
(en)
*
|
2008-01-11 |
2013-01-01 |
Novartis Ag |
Organic compounds
|
|
FR2945806B1
(fr)
*
|
2009-05-19 |
2013-04-05 |
Sanofi Aventis |
Nouveaux derives imidazo[1,2-a]pyridine,procede de preparation,medicaments,compositions pharmaceutiques et utilisation notamment comme inhibiteurs de met
|
|
CN102159559A
(zh)
*
|
2008-07-18 |
2011-08-17 |
赛诺菲-安万特 |
新型咪唑并[1,2-a]吡啶衍生物、其制备方法、其作为药物的用途、其药物组合物和新型用途特别是作为MET抑制剂的新型用途
|
|
EP2430013B1
(en)
*
|
2009-05-13 |
2014-10-15 |
Amgen Inc. |
Heteroaryl compounds as pikk inhibitors
|
|
ES2483594T3
(es)
*
|
2009-07-15 |
2014-08-06 |
Abbott Laboratories |
Pirrolopirazinas inhibidoras de quinasas
|
|
UY33213A
(es)
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
|
US9073918B2
(en)
|
2010-05-20 |
2015-07-07 |
Takeda Pharmaceutical Company Limited |
Pyrazolo[4,3-b]pyridine-7-amine inhibitors of ALK5
|
|
CN102443009B
(zh)
*
|
2010-09-30 |
2014-04-16 |
山东轩竹医药科技有限公司 |
并环激酶抑制剂
|
|
EP2463289A1
(en)
|
2010-11-26 |
2012-06-13 |
Almirall, S.A. |
Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
|
|
SG195100A1
(en)
*
|
2011-07-01 |
2013-12-30 |
Bayer Ip Gmbh |
Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
|
|
EP2554544A1
(en)
|
2011-08-01 |
2013-02-06 |
Almirall, S.A. |
Pyridin-2(1h)-one derivatives as jak inhibitors
|
|
WO2013102142A1
(en)
|
2011-12-28 |
2013-07-04 |
Global Blood Therapeutics, Inc. |
Substituted benzaldehyde compounds and methods for their use in increasing tissue oxygenation
|
|
HK1203412A1
(en)
|
2011-12-28 |
2015-10-30 |
Global Blood Therapeutics, Inc. |
Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
|
|
GB201205669D0
(en)
*
|
2012-03-30 |
2012-05-16 |
Agency Science Tech & Res |
Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
|
|
US10280168B2
(en)
|
2012-03-30 |
2019-05-07 |
Agency For Science, Technology And Research |
Bicyclic heteroaryl derivatives as MNK1 and MNK2 modulators and uses thereof
|
|
RS58514B1
(sr)
|
2012-06-13 |
2019-04-30 |
Incyte Holdings Corp |
Supstituisana triciklična jedinjenja kao inhibitori fgfr
|
|
JP6430383B2
(ja)
*
|
2012-09-28 |
2018-11-28 |
ヴァンダービルト ユニバーシティーＶａｎｄｅｒｂｉｌｔ Ｕｎｉｖｅｒｓｉｔｙ |
選択的ｂｍｐ阻害剤としての縮合複素環化合物
|
|
WO2014145040A1
(en)
|
2013-03-15 |
2014-09-18 |
Global Blood Therapeutics, Inc. |
Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
|
|
AP2015008718A0
(en)
|
2013-03-15 |
2015-09-30 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US9458139B2
(en)
|
2013-03-15 |
2016-10-04 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US8952171B2
(en)
|
2013-03-15 |
2015-02-10 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US9802900B2
(en)
|
2013-03-15 |
2017-10-31 |
Global Blood Therapeutics, Inc. |
Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
|
|
US20140274961A1
(en)
|
2013-03-15 |
2014-09-18 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US9422279B2
(en)
|
2013-03-15 |
2016-08-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US9604999B2
(en)
|
2013-03-15 |
2017-03-28 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
SG10201802911RA
(en)
|
2013-03-15 |
2018-05-30 |
Global Blood Therapeutics Inc |
Compounds and uses thereof for the modulation of hemoglobin
|
|
US10266551B2
(en)
|
2013-03-15 |
2019-04-23 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
EP3919056B1
(en)
|
2013-03-15 |
2024-08-28 |
Global Blood Therapeutics, Inc. |
Compounds and uses thereof for the modulation of hemoglobin
|
|
PH12015502383B1
(en)
|
2013-04-19 |
2023-02-03 |
Incyte Holdings Corp |
Bicyclic heterocycles as fgfr inhibitors
|
|
WO2015031285A1
(en)
*
|
2013-08-27 |
2015-03-05 |
Global Blood Therapeutics, Inc. |
Crystalline 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde ansolvate salts
|
|
EA202092627A1
(ru)
|
2013-11-18 |
2021-09-30 |
Глобал Блад Терапьютикс, Инк. |
Соединения и их применения для модуляции гемоглобина
|
|
ES2860648T5
(es)
|
2014-02-07 |
2024-11-27 |
Global Blood Therapeutics Inc |
Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
|
|
MA41551A
(fr)
|
2015-02-20 |
2017-12-26 |
Incyte Corp |
Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
|
|
MA41841A
(fr)
|
2015-03-30 |
2018-02-06 |
Global Blood Therapeutics Inc |
Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
|
|
WO2017024406A1
(en)
|
2015-08-11 |
2017-02-16 |
Neomed Institute |
N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
|
|
JP2018527340A
(ja)
|
2015-08-11 |
2018-09-20 |
ネオメド インスティテュートＮｅｏｍｅｄ Ｉｎｓｔｉｔｕｔｅ |
アリール置換ジヒドロキノリノン、その調製及び医薬品としてのその使用
|
|
KR102784592B1
(ko)
|
2015-08-12 |
2025-03-19 |
에피제네틱스, 인크. |
치환된 벤즈이미다졸, 그의 제조법 및 제약으로서의 그의 용도
|
|
US10501459B2
(en)
|
2015-10-21 |
2019-12-10 |
Neomed Institute |
Substituted imidazo[1,2-a]pyridines as bromodomain inhibitors
|
|
US11020382B2
(en)
|
2015-12-04 |
2021-06-01 |
Global Blood Therapeutics, Inc. |
Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
|
|
US10519151B2
(en)
|
2016-01-28 |
2019-12-31 |
Neomed Institute |
Substituted [1,2,4]triazolo[4,3-A]pyridines, their preparation and their use as pharmaceuticals
|
|
TWI825524B
(zh)
|
2016-05-12 |
2023-12-11 |
美商全球血液治療公司 |
用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
|
|
US11352328B2
(en)
|
2016-07-12 |
2022-06-07 |
Arisan Therapeutics Inc. |
Heterocyclic compounds for the treatment of arenavirus
|
|
US20190218214A1
(en)
*
|
2016-09-14 |
2019-07-18 |
Vanderbilt University |
Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
|
|
TW202332423A
(zh)
|
2016-10-12 |
2023-08-16 |
美商全球血液治療公司 |
包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
|
|
AR111960A1
(es)
|
2017-05-26 |
2019-09-04 |
Incyte Corp |
Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
|
|
BR112020015396A2
(pt)
|
2018-01-29 |
2020-12-08 |
Merck Patent Gmbh |
Inididores de gcn2 e usos dos mesmos
|
|
WO2019178383A1
(en)
|
2018-03-14 |
2019-09-19 |
Vanderbilt University |
Inhibition of bmp signaling, compounds, compositions and uses thereof
|
|
HRP20241288T1
(hr)
|
2018-05-04 |
2024-12-06 |
Incyte Corporation |
Čvrsti oblici fgfr inhibitora i postupci za njihovu proizvodnju
|
|
AU2019262579B2
(en)
|
2018-05-04 |
2024-09-12 |
Incyte Corporation |
Salts of an FGFR inhibitor
|
|
EP3860975B1
(en)
|
2018-10-01 |
2023-10-18 |
Global Blood Therapeutics, Inc. |
Modulators of hemoglobin for the treatment of sickle cell disease
|
|
US12419865B2
(en)
|
2018-12-06 |
2025-09-23 |
Arisan Therapeutics Inc. |
Compounds for the treatment of arenavirus infection
|
|
CA3124088A1
(en)
*
|
2018-12-20 |
2020-06-25 |
Incyte Corporation |
Imidazopyridazine and imidazopyridine compounds as inhibitors of activin receptor-like kinase-2
|
|
US11628162B2
(en)
|
2019-03-08 |
2023-04-18 |
Incyte Corporation |
Methods of treating cancer with an FGFR inhibitor
|
|
US11591329B2
(en)
|
2019-07-09 |
2023-02-28 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
EP4006027B1
(en)
*
|
2019-07-26 |
2025-10-01 |
CGeneTech (Suzhou, China) Co., Ltd. |
Pyridine derivative as fgfr and vegfr dual inhibitors for the treatment of cancer
|
|
WO2021067374A1
(en)
|
2019-10-01 |
2021-04-08 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
EP4041399A1
(en)
|
2019-10-02 |
2022-08-17 |
Tolremo Therapeutics AG |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment or amelioration of cancer
|
|
WO2021076728A1
(en)
|
2019-10-16 |
2021-04-22 |
Incyte Corporation |
Bicyclic heterocycles as fgfr inhibitors
|
|
CA3163875A1
(en)
|
2019-12-04 |
2021-06-10 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
JP7832891B2
(ja)
|
2019-12-04 |
2026-03-18 |
インサイト・コーポレイション |
Ｆｇｆｒ阻害剤の誘導体
|
|
CN111116582B
(zh)
*
|
2019-12-18 |
2022-07-29 |
大连大学 |
一种mGluR2拮抗剂
|
|
US12612371B2
(en)
|
2019-12-19 |
2026-04-28 |
Universite De Strasbourg |
Sigma-1 receptor ligands and therapeutic uses thereof
|
|
JP2023509760A
(ja)
|
2020-01-08 |
2023-03-09 |
シンシス セラピューティクス，インコーポレイテッド |
Ａｌｋ５阻害剤複合体およびその使用
|
|
US12012409B2
(en)
|
2020-01-15 |
2024-06-18 |
Incyte Corporation |
Bicyclic heterocycles as FGFR inhibitors
|
|
WO2021147699A1
(zh)
*
|
2020-01-21 |
2021-07-29 |
四川科伦博泰生物医药股份有限公司 |
吡啶并杂环类化合物、其制备方法及用途
|
|
CA3184811A1
(en)
|
2020-06-12 |
2021-12-16 |
Incyte Corporation |
Imidazopyridazine compounds with activity as alk2 inhibitors
|
|
WO2021260110A1
(en)
*
|
2020-06-25 |
2021-12-30 |
Tolremo Therapeutics Ag |
Heterocyclic derivatives, pharmaceutical compositions and their use in the treatment, amelioration or prevention of fibrotic disease
|
|
KR20230028798A
(ko)
|
2020-06-25 |
2023-03-02 |
톨레모 테라퓨틱스 아게 |
암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
|
|
EP4182323B1
(en)
|
2020-07-15 |
2024-04-24 |
Chiesi Farmaceutici S.p.A. |
Pyrido oxazine amino derivatives as alk5 inhibitors
|
|
ES2982017T3
(es)
|
2020-07-15 |
2024-10-14 |
Chiesi Farm Spa |
Derivados de pirido-oxazina como inhibidores de ALK5
|
|
EP4182308B1
(en)
|
2020-07-15 |
2024-09-04 |
Chiesi Farmaceutici S.p.A. |
Pyridazinyl amino derivatives as alk5 inhibitors
|
|
EP4267584A1
(en)
|
2020-12-23 |
2023-11-01 |
Chiesi Farmaceutici S.p.A. |
Pyrido oxazine derivatives as alk5 inhibitors
|
|
CA3206502A1
(en)
*
|
2021-01-26 |
2022-08-04 |
Zhengxia CHEN |
Crystal form of methylpyrazole-substituted pyridoimidazole compound and preparation method therefor
|
|
IL307402A
(en)
|
2021-04-07 |
2023-12-01 |
Tolremo Therapeutics Ag |
The tercyclic derivatives, pharmaceutical compounds and their use in the treatment or amelioration of cancer
|
|
WO2022221170A1
(en)
|
2021-04-12 |
2022-10-20 |
Incyte Corporation |
Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent
|
|
CA3220155A1
(en)
|
2021-06-09 |
2022-12-15 |
Incyte Corporation |
Tricyclic heterocycles as fgfr inhibitors
|
|
US11939331B2
(en)
|
2021-06-09 |
2024-03-26 |
Incyte Corporation |
Tricyclic heterocycles as FGFR inhibitors
|
|
US20250011299A1
(en)
|
2021-09-21 |
2025-01-09 |
Chiesi Farmaceutici S.P.A. |
Pyridazinyl amino derivatives as alk5 inhibitors
|
|
CA3225500A1
(en)
|
2021-10-04 |
2023-04-13 |
Ulrich Luecking |
Parg inhibitory compounds
|
|
EP4514802A1
(en)
|
2022-04-27 |
2025-03-05 |
Chiesi Farmaceutici S.p.A. |
Imidazole derivatives as alk5 inhibitors
|
|
KR20250073643A
(ko)
|
2022-10-03 |
2025-05-27 |
포알엑스 테라퓨틱스 아게 |
Parg 억제 화합물
|
|
EP4688159A1
(en)
|
2023-04-05 |
2026-02-11 |
FoRx Therapeutics AG |
Parg inhibitory compounds
|
|
CN121712526A
(zh)
|
2023-06-13 |
2026-03-20 |
辛瑟斯治疗股份有限公司 |
抗cd5抗体及其用途
|
|
CN121889393A
(zh)
|
2023-10-03 |
2026-04-17 |
福克斯治疗股份公司 |
Parg抑制化合物
|